Osteosarcoma

Osteosarcoma is the most common primary malignant bone tumor, most frequently affecting adolescents and young adults. This article explains what osteosarcoma is, its symptoms, diagnosis, modern treatment options, and long‑term outlook based on current medical practice.

What Is Osteosarcoma?

• Osteosarcoma is a cancer that begins in the cells that form bone, producing immature bone tissue (osteoid).
• It most often arises in the long bones of the arms and legs, especially around the knee (distal femur, proximal tibia).
• The disease peaks during the adolescent growth spurt, likely because rapid bone turnover triggers malignant transformation.
• Less commonly, osteosarcoma occurs in adults older than 60, often secondary to Paget disease of bone or prior radiation therapy.

Signs and Symptoms of Osteosarcoma

• Persistent, localized bone pain – often worse at night or with activity – is the earliest and most common symptom.
• Swelling or a palpable lump over the affected bone may appear weeks after the pain starts.
• Limping or restricted range of motion, especially when the tumor involves a joint, is frequently noted.
• Pathological fracture (a break through the weakened bone) can occur in about 10–15% of patients and is often the first sign.

Common Misdiagnoses

• Growing pains, sports injuries, or benign bone tumors like osteochondroma are often mistaken for osteosarcoma.
• Delayed diagnosis happens because early symptoms mimic non‑cancerous conditions. Any persistent bone pain lasting more than a few weeks warrants medical imaging.

The following table contrasts typical symptoms of osteosarcoma with those of more common benign conditions.

How Is Osteosarcoma Diagnosed?

• Imaging begins with plain X‑rays of the painful area; magnetic resonance imaging (MRI) of the whole bone and adjacent joint helps define tumor extent.
• Computed tomography (CT) of the chest is mandatory to look for lung metastases, the most common site of spread.
• A biopsy – usually a core needle biopsy – is the only definitive way to confirm osteosarcoma. The biopsy tract must be planned carefully to allow later surgical removal.
• Blood tests (alkaline phosphatase and lactate dehydrogenase) are not diagnostic but may correlate with tumor burden and prognosis.

“A timely, properly performed biopsy is the cornerstone of osteosarcoma management. A mismanaged biopsy can compromise limb‑salvage options and patient survival.” – Dr. Elena Torres, orthopedic oncologist

Treatment Options for Osteosarcoma

• Neoadjuvant chemotherapy (given before surgery) shrinks the primary tumor and treats micrometastases. Standard regimens include high‑dose methotrexate, doxorubicin, and cisplatin.
• Surgery aims for wide local excision with clear margins. Limb‑salvage procedures are now possible in more than 90% of patients, using metal endoprostheses or biologic reconstructions.
• Adjuvant chemotherapy (after surgery) is given to eliminate any remaining cancer cells. The total chemotherapy duration is about 6–9 months.
• Radiation therapy plays a limited role – mainly for tumors that cannot be completely resected (e.g., in the spine or base of skull) or for palliative control.
• Emerging therapies include immune checkpoint inhibitors (e.g., pembrolizumab) and targeted agents (e.g., inhibitors of the IGF‑1R pathway) for relapsed or refractory disease, though none are yet first‑line standard of care.

“The goal of modern osteosarcoma care is not just to cure the cancer, but to preserve function and quality of life. Limb‑salvage surgery has transformed outcomes, but it requires a skilled multidisciplinary team.” – Dr. Marcus Li, surgical oncologist

Prognosis and Survival Rates

• For localized osteosarcoma at diagnosis, the long‑term survival rate is approximately 65–70% with modern multimodality therapy.
• Patients who present with metastases (about 15–20% at diagnosis) have a poorer outlook, with survival below 30%.
• Key prognostic factors: tumor size, location (axial tumors fare worse), response to preoperative chemotherapy (greater than 90% necrosis is favorable), and surgical margin status.
• Relapse occurs most often within the first two years after treatment, and metastatic relapse (especially to lungs) remains the main cause of death.

Living with Osteosarcoma

• Long‑term follow‑up includes regular chest X‑rays or CT scans to detect late metastases, as well as monitoring for implant‑related problems (loosening, infection, fracture).
• Rehabilitation after limb‑salvage surgery involves physical therapy to regain strength and range of motion; some patients require walking aids permanently.
• Psychological support is critical – survivors often face depression, anxiety about recurrence, and body‑image concerns.
• Advances in prosthetics and adaptive sports allow many patients to return to an active life, including competitive athletics in some cases.

In summary, osteosarcoma demands prompt recognition, accurate biopsy, and intensive multidisciplinary care. Outcomes have steadily improved, but challenges remain, particularly for metastatic and relapsed disease. Ongoing clinical trials investigating immunotherapy, novel drug combinations, and better surgical techniques offer hope for even higher cure rates and less long‑term disability.

Frequently Asked Questions About Osteosarcoma

What is the main cause of osteosarcoma?

The exact cause is unknown. Most cases occur sporadically. Certain inherited syndromes (e.g., Li‑Fraumeni, hereditary retinoblastoma) and prior radiation exposure increase risk, but the majority of patients have no identifiable cause.

Is osteosarcoma painful at night?

Yes. Night pain is a classic symptom. The pain often wakes the patient and may not respond well to over‑the‑counter pain relievers. Persistent night‑time bone pain should always be investigated.

Can osteosarcoma spread to other parts of the body?

Yes. The most common site of metastasis is the lungs, followed by other bones. Spread to lymph nodes is rare. At diagnosis, about 15–20% of patients already have detectable lung metastases.

How is osteosarcoma different from Ewing sarcoma?

Both are primary bone cancers but arise from different cell types. Osteosarcoma produces osteoid (immature bone), while Ewing sarcoma is a small round‑cell tumor driven by EWSR1‑FLI1 gene fusions. Their age distribution, imaging appearance, and chemotherapy regimens also differ.

Is amputation still necessary for osteosarcoma?

In the past, amputation was the standard. Today, limb‑salvage surgery is possible in more than 90% of patients. Amputation is reserved for tumors that involve major nerves, blood vessels, or if the patient prefers a quicker recovery without the risks of limb reconstruction.

What is the survival rate for osteosarcoma in children?

For children with localized disease, the five‑year survival rate is approximately 70%. Younger age and good response to chemotherapy improve outcomes. Metastatic disease still carries a much lower survival rate.

Can osteosarcoma come back after treatment?

Yes, relapse occurs in about 30–40% of patients, usually within the first two years. Relapse most often appears as lung metastases. Treatment for recurrence may include further surgery, second‑line chemotherapy, or radiation.

What are the long‑term side effects of chemotherapy for osteosarcoma?

Common long‑term effects include heart damage (from doxorubicin), hearing loss (from cisplatin), kidney impairment, and a small risk of secondary cancers. Regular monitoring by a survivorship clinic is recommended.

Is there a role for immunotherapy in osteosarcoma?

Immunotherapy is not yet standard for frontline treatment. However, immune checkpoint inhibitors (e.g., pembrolizumab) are being tested in clinical trials for relapsed or refractory osteosarcoma. Some tumors with high mutational burden may respond.

Can osteosarcoma be prevented?

There is no known prevention strategy. Avoiding unnecessary radiation exposure and early evaluation of persistent bone pain may lead to earlier diagnosis, but primary prevention is not currently possible.